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Background: Breast cancer is the most common cancer in younger women (aged p40 years) in the United Kingdom. PREDICT
(http://www.predict.nhs.uk) is an online prognostic tool developed to help determine the best available treatment and outcome
for early breast cancer. This study was conducted to establish how well PREDICT performs in estimating survival in a large cohort
of younger women recruited to the UK POSH study.
Methods: The POSH cohort includes data from 3000 women aged p40 years at breast cancer diagnosis. Study end points were
overall and breast cancer-specific survival at 5, 8, and 10 years. Evaluation of PREDICT included model discrimination and
comparison of the number of predicted versus observed events.
Results: PREDICT provided accurate long-term (8- and 10-year) survival estimates for younger women. Five-year estimates were
less accurate, with the tool overestimating survival by 25% overall, and by 56% for patients with oestrogen receptor (ER)-positive
tumours. PREDICT underestimated survival at 5 years among patients with ER-negative tumours.
Conclusions: PREDICT is a useful tool for providing reliable long-term (10-year) survival estimates for younger patients.
However, for more accurate short-term estimates, the model requires further calibration using more data from young onset
cases. Short-term prediction may be most relevant for the increasing number of women considering risk-reducing bilateral
mastectomy.
Breast cancer is the most common cancer in women in the United
Kingdom, with around 50 000 newly diagnosed cases each year
(Cancer Research UK, 2014). Approximately 4% of cases are in
younger women (aged p40 years at diagnosis) yet it remains the
most frequent malignancy in women of this age group (Cancer
Research UK, 2014).
Determining the long-term outcome and potential benefits from
systemic adjuvant treatments for early-stage breast cancer has
been improved through the use of a number of currently available
predictive tools, including the Nottingham Prognostic Index (NPI),
Adjuvant! and PREDICT. These tools have become increasingly
sophisticated; incorporating a growing number of prognostic
factors, enabling a move from categorising patients into broad
prognostic groups to providing survival estimates at a patient level.
However, many existing prognostic tools have only been validated
in a small number of younger women, in which an overestimation
of up to 30% in overall survival (OS) is reported in younger women
(Engelhardt et al, 2014).
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MATERIALS AND METHODS
Existing tools. The original NPI was based on 387 patients treated
in a single institution and used tumour size, grade, and lymph node
status to provide a prognostic index (Haybittle et al, 1982). The
tool was later validated (Todd et al, 1987; D’Eredita et al, 2001) and
updated to provide survival estimates by NPI group (Blamey et al,
2007a), and at a patient level (Blamey et al, 2007b).
Adjuvant! is an online decision aid tool, which was developed in
2001, based on 34 252 women aged 36–69 years from multiple
institutions in the United States, and incorporated the patient’s age,
tumour size and grade, oestrogen receptor (ER) status, and number
of positive nodes, to provide individual 10-year outcomes (Ravdin
et al, 2001). The tool was later validated in patients from Canada
(Olivotto et al, 2005) and the United Kingdom (Campbell et al,
2009). Adjuvant! makes an adjustment for women under 35 years,
based on data from 415 patients; however, this applies only to
patients with ER-positive tumours (Aebi et al, 2000).
The online breast cancer prognostic and treatment benefit tool,
PREDICT, is used to estimate survival for individual patients based
on known pathological prognostic factors, including age at diagnosis,
mode of detection, tumour grade, tumour size, ER and nodal status,
and type of therapy. The tool was developed in the United Kingdom,
based on 5694 women aged 23–95 years (401 agedp40 years), from
multiple institutions in East Anglia, and validated in two further
cohorts: 5468 women aged 22–93 years from the West Midlands
Cancer Intelligence Unit (Wishart et al, 2010); and the same cohort
used for the validation of Adjuvant! (Wishart et al, 2011).
An updated version of PREDICT (http://www.predict.nhs.uk)
now incorporates human epidermal growth factor receptor 2
(HER2) status (Wishart et al, 2012). The updated tool was
validated using 1653 patients with information on HER2 from the
same cohort of 3140 women from Canada used in the previous
validations of PREDICT and Adjuvant!, and was shown to provide
accurate OS and breast cancer-specific survival (BCSS) estimates at
10 years. The results demonstrated that the incorporation of HER2
status improved the tool, with predicted overall and breast cancer-
specific deaths within 8.4% and 2.5% of those observed (P¼ 0.05
and P¼ 0.60, respectively). However, the results indicated that
PREDICT underestimated the number of deaths in women aged
20–35 years by 32% for both OS and BCSS (Wishart et al, 2012).
Although PREDICT was successfully validated in a large cohort,
only 159 (9.6%) of these women from Canada were agedp40 years
at diagnosis. However, young age at diagnosis is associated with
lower survival rates compared with older patients (El Saghir et al,
2006; Adami et al, 1986). The reasons for the differing effects remain
unclear; studies have shown that lower survival rates coupled with
higher relapse rates in younger patients are independent of other
known prognostic factors (de la Rochefordiere et al, 1993; Nixon
et al, 1994). Younger patients may receive less significant survival
benefits from hormonal therapy after adjuvant chemotherapy
than older patients (Ahn et al, 2007). Furthermore, studies of
premenopausal and perimenopausal women with breast cancer have
found that chemotherapy alone was insufficient for younger
patients, and perhaps tailored treatments should be investigated
(Aebi et al, 2000; Colleoni et al, 2006).
The aim of this study was to investigate the performance of the
updated PREDICT tool in a large cohort of women agedp40 years
at breast cancer diagnosis in terms of model calibration and
discrimination for both OS and BCSS.
Study population. POSH is a multicentre prospective observa-
tional cohort study of 3000 young women diagnosed with breast
cancer in the United Kingdom between 2000 and 2008
(http://www.southampton.ac.uk/medicine/research/posh.page).
The detailed study protocol was published in 2007 (Eccles et al,
2007), and the cohort has previously been described (Copson et al,
2013a).
Information obtained in the POSH cohort included age at
diagnosis, ethnicity (Caucasian/white, black, Asian, other, missing/
unknown), menopausal status (pre-, peri-, and post-menopausal,
or missing/unknown), family history of breast cancer, ER,
progesterone receptor, and HER2 status, histology, histological
grade, tumour size, number of positive lymph nodes, lymphovas-
cular invasion status, focality (localised, multifocal, missing/
unknown), presentation, gene status (BRCA1, BRCA2, other, not
tested/missing/unknown), and type of adjuvant therapy. This
article presents analyses conducted on follow-up data from the
POSH cohort received until 22 October 2013.
Study end points were OS and BCSS at 5, 8, and 10 years, where
OS is defined as time from breast cancer diagnosis to death from any
cause, and BCSS as time to death from breast cancer (deaths from
other causes were censored at the time of last follow-up). The cohort
includes data from 2827, 1843, and 597 patients with key prognostic
information needed for the analyses for OS at 5, 8, and 10 years,
respectively. Cause of death was missing for 5 patients leaving 2822,
1841, and 595 patients for analyses for BCSS, respectively.
Predicted OS and BCSS were calculated for each patient using
PREDICT by investigators blinded to actual patient outcomes. Age
at diagnosis, tumour size, and number of positive lymph nodes
were entered as continuous variables. Categorical variables were
used for presentation (screen-detected, symptomatic, or unknown),
histological grade (1, 2, 3, or unknown), ER status (negative
(ER ) or positive (ERþ )), HER2 (negative (HER2 ), positive
(HER2þ ), or unknown), and chemotherapy regimen (second
generation or third generation).
Model calibration and discrimination. Using a similar approach
to the methods applied in previous validations of PREDICT
(Wishart et al, 2011, 2012), predicted OS and BCSS were compared
with the corresponding observed OS and BCSS at 5, 8, and 10
years. Model calibration, a comparison between the predicted and
observed mortality, was evaluated for the complete data set, by
quartiles of the predicted mortality and also within strata (Wishart
et al, 2012). As evidence suggests that existing prognostic tools do
not perform well in Asian patients (Engelhardt et al, 2014), and
black ethnicity was found to be an independent risk factor for
reduced survival in younger women (Copson et al, 2013b), model
calibration was also evaluated across ethnic groups. Goodness-of-
fit tests were performed using w2 tests based on the number of
predicted and observed events (4 d.f.). Model discrimination was
assessed by calculating the area under the receiver-operator
characteristic curve (AUC) and corresponding 95% confidence
intervals for 5-, 8-, and 10-year predicted all-cause mortality and
breast cancer-specific mortality. The AUC is the probability that
the predicted mortality of a randomly selected patient who died is
higher than that of a randomly selected patient who survived; the
higher the AUC, the better the model is at identifying patients with
a worse survival (Wishart et al, 2012).
All analyses were performed using STATA v12.1 (StataCorp LP,
College Station, TX, USA).
RESULTS
Model calibration. The demographic, tumour, and treatment
information at baseline together with the predicted and observed
all-cause OS at 5, 8, and 10 years are shown in Table 1. Overall,
PREDICT did not perform well at 5 years, with an underestimation
of the total number of deaths by 25% (455 vs 607, Po0.001), and
within most subgroups; most notably in patients with grade 2
tumours (58%; 67 vs 161, Po0.001), 0–10mm tumours (52%; 20 vs
42, P¼ 0.001), ERþ tumours (56%; 158 vs 362, Po0.001), and
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Table 1. Observed and predicted 5-, 8-, and 10-year all-cause mortality by demographical, tumour ,and treatment characteristics
5 Years 8 Years 10 Years
Characteristic N O P D % N O P D % N O P D %
Total 2827 607 455  152  25 1843 454 430  24  5.3 597 152 164 12 7.9
Age at diagnosis (years)
18–25 40 7 5  2  28.6 21 4 4 0 0 8 1 1 0 0
26–30 258 62 46  16  25.8 167 48 43  5  10.4 55 15 16 1 6.7
31–35 864 210 152  58  27.6 580 168 146  22  13.1 203 60 57  3 5
36–40 1665 328 252  76  23.2 1075 234 237 3 1.3 331 76 90 14 18.4
Menopausal status
Premenopause 2771 591 444  147  24.9 1801 440 420  20  4.5 581 148 162 14 9.5
Post-menopause 7 2 1  1  50 4 2 1  1  50 1 1 0  1 100
Perimenopause 5 2 1  1  50 5 2 2 0 0 3 1 1 0 0
Unknown 44 12 9  3  25 33 10 8  2  20 12 2 2 0 0
Morphology
Ductal 2447 531 410  121  22.8 1606 396 388  8  2 520 132 149 17 12.9
Lobular 129 27 10  17  63 79 21 12  9  42.9 30 8 4  4 50
Other 216 42 31  11  26.2 133 32 27  5  15.6 40 12 10  2 16.7
Unknown 35 7 4  3  42.9 25 5 4  1  20 7 0 1 1 .
Grade
1 156 5 4  1  20 98 5 4  1  20 31 3 2  1 33
2 929 161 67  94  58.4 614 121 75  46  38 200 44 31  13 30
3 1676 429 378  51  11.9 1097 322 346 24 7.5 351 103 129 26 25.2
Not graded/missing 66 12 7  5  41.7 34 6 5  1  16.7 15 2 2 0 0
LV invasion
Negative 1374 182 156  26  14.3 873 142 144 2 1.4 290 47 59 12 25.5
Positive 1253 385 272  113  29.4 845 287 264  23  8 270 96 99 3 3.1
Unknown 200 40 27  13  32.5 125 25 22  3  12 37 9 7  2 22
Node status
Negative 1370 161 128  33  20.5 869 111 115 4 3.6 266 39 42 3 7.7
Positive 1431 439 324  115  26.2 959 339 312  27  8 327 112 121 9 8
Unknown 26 7 4  3  42.9 15 4 3  1  25 4 1 1 0 0
Tumour size
0–10 265 42 20  22  52.4 161 29 17  12  41.4 48 14 7  7 50
11–20 930 125 100  25  20 629 99 99 0 0 221 41 45 4 9.8
21–50 1229 302 233  69  22.8 798 228 219  9  3.9 244 78 79 1 1.3
50þ 244 99 85  14  14.1 171 75 83 8 10.7 54 13 28 15 115.4
Unknown 159 39 16  23  59 84 23 12  11  47.8 30 6 5  1 16.7
ER status
Negative 965 245 297 52 21.2 642 183 242 59 32.2 231 64 94 30 46.9
Positive 1862 362 158  204  56.4 1201 271 188  83  30.6 366 88 70  18 20.5
Local Rx
BCSþRT 1310 188 168  20  10.6 872 146 159 13 8.9 275 59 59 0 0
MastþRT 1001 313 228  85  27.2 648 231 213  18  7.8 208 70 85 15 21.4
Mast alone 445 87 48  39  44.8 277 65 47  18  27.7 101 22 18  4 18.2
Other 71 19 12  7  36.8 46 12 10  2  16.7 13 1 3 2 200
Systemic Rx
None 46 4 5 1 25 28 3 5 2 66.7 6 1 1 0 0
Hormone 227 16 6  10  62.5 157 15 8  7  46.7 50 6 3  3 50
Chemo 986 261 297 36 13.8 659 198 248 50 25.3 237 71 94 23 32.4
Both 1568 326 147  179  54.9 999 238 170  68  28.6 304 74 66  8 10.8
HER2 status
Negative 1773 383 255  128  33.4 1059 273 234  39  14.3 327 82 83 1 1.2
Positive 679 183 159  24  13.1 434 141 141 0 0 140 50 53 3 6
Borderline 40 10 6  4  40 33 10 7  3  30 14 5 4  1 20
Unknown 335 31 35 4 12.9 317 30 49 19 63.3 116 15 24 9 60
Ethnicity
Caucasian/White 2582 547 413  134  24.5 1692 411 392  19  4.6 557 144 156 12 8.3
Black 110 36 21  15  41.7 74 27 20  7  25.9 17 5 4  1 20
Asian 84 15 14  1  6.7 55 11 13 2 18.2 16 3 3 0 0
Other 19 3 3 0 0 12 3 3 0 0 3 0 0 0 .
Unknown 32 6 5  1  16.7 10 2 2 0 0 4 0 1 1 .
Abbreviations: BCS¼breast-conserving surgery; D¼difference; ER¼oestrogen receptor status; HER2¼human epidermal growth factor receptor 2; LV=lymphovascular invasion; N¼number
of patients; O¼number of observed events; P¼ number of predicted events; RT¼ radiotherapy; Rx¼Treatment.
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patients receiving both hormone and chemotherapy (55%; 147 vs
326, Po0.001). Conversely, PREDICT overestimated the number
of deaths by 21% (297 vs 245, P¼ 0.0009) in patients with ER
tumours and patients receiving adjuvant trastuzumab (data not
shown) by 25% (86 vs 69, P¼ 0.041). Across HER2 and ethnicity
subgroups, PREDICT was found to underestimate all-cause
mortality in HER2 tumours, Caucasian/white and Black
ethnicity (33%; 255 vs 383, Po0.001, 25%; 413 vs 547, Po0.001,
and 42%; 21 vs 36, P¼ 0.012 respectively), and slightly under-
estimated for HER2þ and borderline tumours. In addition, when
looking at chemotherapy regimen (data not shown) the tool was
found to underestimate the number of deaths by 28% (297 vs 410,
Po0.001) and by 18% (146 vs 177, P¼ 0.020) for patients receiving
second- and third-generation chemotherapy, respectively. Despite
a poor performance across most subgroups at 5 years, the tool did
perform well in certain subgroups; notably in patients with
tumours 450mm (14% underestimation; 85 vs 99, P¼ 0.159),
patients receiving both radiotherapy and breast conserving surgery
(11% underestimation; 168 vs 188, P¼ 0.145), and in Asian
patients (7% underestimation; 14 vs 15, P¼ 0.796).
At 8 years, the performance of PREDICT considerably
improved, with the difference between the predicted deaths within
6% of those observed across the entire cohort (430 vs 454,
P¼ 0.260), and the tool performing well across most subgroups.
Notable improvements to the predicted all-cause mortality from 5
to 8 years were found in patients aged 36–40 years (23%, Po0.001,
to 1%, P¼ 0.845), patients with a ductal morphology (23%,
Po0.001, to 2%, P¼ 0.688), negative nodal status (21%, P¼ 0.009,
to 4%, P¼ 0.704), 21–50mm tumours (23%, Po0.001, to 4%,
P¼ 0.551), patients who had radiotherapy and a mastectomy (27%,
Po0.001, to 8%, P¼ 0.236), and patients receiving second- or
third-generation chemotherapy (28%, Po0.001, to 7%, P¼ 0.201
and 18%, P¼ 0.020, to 4%, P¼ 0.705, respectively). The perfor-
mance of the tool had also greatly improved across all ethnicity
subgroups and in patients with HER2þ and borderline tumours.
The number of predicted deaths remained much lower than those
observed for patients with grade 2 tumours, 0–10mm tumours,
patients with a lobular morphology, and patients receiving both
hormone and chemotherapy. There was also greater disparity in
the predicted vs observed number of deaths at 8 years compared
with 5 years when looking at patients receiving adjuvant
trastuzumab and at ER subgroups, with all-cause mortality
overestimated for patients receiving adjuvant trastuzumab by
58% (52 vs 33, P¼ 0.001), and overestimated for ER tumours by
32% (242 vs 183, Po0.001) and underestimated for ERþ tumours
by 31% (188 vs 271, Po0.001).
In contrast to the underestimation of the total number of deaths
at 5 and 8 years, PREDICT was found to overestimate the number
of deaths at 10 years by 8% (164 vs 152, P¼ 0.330). The number of
deaths remained overestimated for patients with ER tumours
(47%; 94 vs 64, Po0.001), grade 3 tumours (25%; 129 vs 103,
P¼ 0.010), and tumours larger than 50mm (115%; 28 vs 13,
Po0.001). In addition, the tool was found to overestimate all-cause
mortality in patients aged 36–40 years (18%; 90 vs 76, P¼ 0.108),
patients with grade 3 tumours (25%; 129 vs 103, P¼ 0.010) and
tumours without lymphovascular invasion (26%; 59 vs 47,
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Figure 1. Calibrations plots of observed OS outcomes with 95% confidence intervals against predicted outcomes by quartiles of the predicted
risk, by ER status.OS outcomes for patients with ER tumours at (A) 5 years, (B) 8 years, and (C) 10 years, and OS outcomes for patients with ERþ
tumours at (D) 5 years, (E) 8 years, and (F) 10 years.
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P¼ 0.080), patients receiving chemotherapy alone (32%; 94 vs 71,
P¼ 0.006), and patients receiving third-generation chemotherapy
(31%; 42 vs 32, P¼ 0.077). Nevertheless, the 10-year estimates
predicted by the tool had much improved across most subgroups,
including ethnicity subgroups and HER2 subgroups.
The number of predicted vs observed breast cancer-specific
deaths was very similar to the results for OS, with no notable
differences between the OS and BCSS results when comparing
these both by year (5, 8, and 10 years) and across subgroups
(Supplementary Table 1).
The comparison between the predicted and observed all-cause
mortality by quartiles of the predicted risk both across years and
split by ER status is presented in Figure 1. PREDICT was found
to overestimate the total number of deaths for patients with
ER tumours but underestimate for the ERþ subgroup.
Goodness-of-fit test P-values identified that PREDICT performed
better at 10 years compared with 5 and 8 years (Po0.001,
P¼ 0.00284, and P¼ 0.0295 for ER tumours at 5, 8, and 10
years, respectively, and Po0.001, Po0.001 and P¼ 0.0183 for
ERþ tumours).
The findings were almost identical when comparing the
predicted and observed breast cancer-specific mortality by year
and ER status (Supplementary Figure 1). Moreover, when
comparing the predicted and observed all-cause mortality by ER
status for patients with HER2 tumours only (Figure 2) and
HER2þ tumours only (Figure 3), the pattern of overestimating
mortality in patients with ER tumours and underestimating
mortality in ERþ tumours remained evident across years. The
overestimation of the tool was also apparent when comparing the
number of predicted vs observed all-cause deaths in patients with
both ER and HER2þ tumours (data not shown), with an
overestimation at 5, 8, and 10 years of 38% (101 vs 73, P¼ 0.001),
39% (78 vs 56, P¼ 0.003), and 68% (32 vs 19, P¼ 0.003),
respectively. For patients with both ER and HER2 tumours,
the overestimation was not as large (8% (P¼ 0.301), 18%
(P¼ 0.060), and 22% (P¼ 0.188), respectively). For patients with
both ERþ and HER2 tumours, large differences between the
predicted and observed deaths could be seen at 5 and 8 years
but not at 10 years. Underestimation was prominent in patients
with both ERþ and HER2þ tumours, with an underestimation
at 5, 8, and 10 years of 46% (59 vs 101, Po0.001), 26%
(63 vs 85, P¼ 0.017), and 32% (21 vs 31, P¼ 0.072),
respectively.
Model discrimination. PREDICT provided a reasonably high
degree of discrimination for OS across years (data not shown) and
when splitting by ER and HER2 status (Figure 4). Model
discrimination was slightly better for patients with ERþ tumours
across all years (AUC: 0.718 vs 0.730, 0.709 vs 0.748, 0.694 vs 0.724
for ER vs ERþ tumours at 5, 8, and 10 years, respectively).
Conversely, model discrimination was better for patients with
HER2 tumours, particularly at 10 years (AUC: 0.724 vs 0.592 for
HER2 vs HER2þ tumours). Similar findings were apparent for
BCSS (Supplementary Figure 2).
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Figure 2. Calibrations plots of observed OS outcomes with 95% confidence intervals against predicted outcomes by quartiles of the predicted
risk for HER2 patients only, by ER status. OS outcomes for patients with ER tumours at (A) 5 years, (B) 8 years, and (C) 10 years, and OS
outcomes for patients with ERþ tumours at (D) 5 years, (E) 8 years, and (F) 10 years.
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DISCUSSION
This study has demonstrated that the prognostic tool PREDICT is
able to provide accurate long-term (8- and 10-year) outcomes for
younger women with breast cancer but provides only limited
accuracy regarding short-term (5-year) survival, for both OS and
BCSS.
High performance in terms of accurate predictions in the
number of deaths was prominent in a number of subgroups across
both years and survival type. These subgroups included patients
receiving both radiotherapy and breast conserving surgery, patients
with grade 1 tumours, HER2þ tumours, and patients with both
ER and HER2 tumours. Although the number of Asian
patients included in the analyses at 5, 8, and 10 years was small
(84, 55, and 16, respectively), PREDICT performed well in this
subgroup of the POSH cohort, which was contrary to previous
findings on a number of prognostic tools (Engelhardt et al, 2014).
Our findings also demonstrated that in Caucasian/white and Black
ethnicity subgroups, PREDICT was able to provide accurate long-
term, but not short-term, estimates.
A key area in which PREDICT could improve its prognostic
ability is in patients with ER tumours. The number of predicted
deaths across both years and survival type was overly pessimistic in
this subgroup as demonstrated by the calibration plots (Figure 1
and Supplementary Figure 1). These results were contrary to the
previously published validation of PREDICT for patients aged
20–85 years, in which the tool was found to accurately predict 10-
year OS and BCSS in the ER subgroup (Wishart et al, 2012).
Splitting the ER subgroup by HER2 status, it was evident that
there is some disparity between the PREDICT estimates for
HER2 and HER2þ patients in this subgroup, with the tool
providing accurate predictions for patients with both ER and
HER2 tumours across years and survival type, while consistently
overestimating the number of deaths for patients with both ER
and HER2þ tumours. In contrast, the tool underestimated the
number of deaths in patients with ERþ tumours, when looking
not only at the subgroup as a whole but also when further splitting
by HER2 status.
In relation to HER2 subgroups overall, the tool was able to
predict the number of deaths for both OS and BCSS to within 1%
of those observed for the HER2 subgroup, with corresponding
10-year AUCs of 0.724 and 0.718, respectively. PREDICT was not
quite as reliable in terms of identifying patients with a worse
survival in the HER2þ subgroup (AUC¼ 0.592 for both 10-year
OS and BCSS), although the predicted number of deaths for OS
and BCSS were within 6% of those observed. Fewer patients with
HER2þ tumours were available in the 10-year evaluation (n¼ 140
for both OS and BCSS) compared with HER2 tumours (n¼ 327
and n¼ 325, respectively), which might have contributed to the
reduction in accuracy of PREDICT for patients with HER2þ
tumours.
In terms of OS and BCSS overall, the findings of our study
demonstrated that PREDICT performs equally well, whereas the
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Figure 3. Calibrations plots of observed OS outcomes with 95% confidence intervals against predicted outcomes by quartiles of the predicted
risk for HER2þ patients only, by ER status. OS outcomes for patients with ER tumours at (A) 5 years, (B) 8 years, and (C) 10 years, and OS
outcomes for patients with ERþ tumours at (D) 5 years, (E) 8 years, and (F) 10 years.
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Wishart et al validation showed that PREDICT is slightly better
at providing BCSS estimates compared with OS estimates
(Wishart et al, 2012). The validation also found that PREDICT
underestimated the number of deaths at 10 years by 32% for
patients aged 20–35 years (Wishart et al, 2012). In contrast to
this, our study of outcomes for patients aged 18–40 years at
diagnosis showed an overestimation in 10-year all-cause mortality
of 8%. We explored this a little further by dichotomising age at
diagnosis into two groups (data not shown), o35 and 35–40
years. Surprisingly, for the group aged o35 years, the number of
deaths predicted (OS) was within 2% of those observed (60 vs 61,
P¼ 0.898) and within 14% (104 vs 91, P¼ 0.173) for patients aged
35–40 years, indicating that differences in response to treatment
between these two age groups could lead to some disparity
between the performance of PREDICT between these two
age groups.
There could be several reasons for the differences found in this
study compared with other studies. The similarity of the OS and
BCSS results of our study is likely due to the fact that competing
mortality does not play as important a role within this age group;
excluding five patients with a missing/unknown cause of death,
over 96% of deaths were due to breast cancer. In addition,
PREDICT was developed to provide long-term (10-year) out-
comes, not short-term, which might explain the reduced accuracy
of the 5-year estimates. A possible reason for poor performance in
patients aged 20–35 years is the low numbers on which the model
was based; only 401 women aged p40 years were used in the
development of PREDICT (131 patients had ER and 270 ERþ
tumours). Furthermore, the number of patients aged p40 years
evaluated in the validation of the enhanced PREDICT tool was
relatively small (n¼ 159; Wishart et al, 2012). It should be noted
that poorer prediction in younger patients is a common finding
across a number of other prognostic tools, which were found to
overestimate OS by up to 30% in younger women (Engelhardt
et al, 2014). As PREDICT did not perform well in a number of
subgroups in our study, including the ER subgroup, further
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Figure 4. ROC curves for OS: split by ER status at (A) 5 years, (B) 8 years, and (C) 10 years; and split by HER2 status at (D) 5 years, (E) 8 years, and (F)
10 years.
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modifications to PREDICT using this larger data set could
improve survival estimates for younger breast cancer patients.
Furthermore, inclusion of the proliferation marker KI67 in the
PREDICT model has led to a statistically significant improvement
in function of the PREDICT model for ERþ patients (Wishart
et al, 2014), which may also improve prognostication for younger
patients.
There are some limitations to our study, which should be taken
into account when interpreting the results. Less than half the
patients from the POSH cohort had reached 10 years from
diagnosis at the time of this analysis and so only a relatively small
number could be included in the 10-year comparison (n¼ 607).
This is, however, still considerably larger than the number of
women aged p40 years in the validation of PREDICT (n¼ 159;
Wishart et al, 2012). Our study also demonstrated an over-
estimation in OS at 10 years so arguably this longer follow-up
may not improve the estimates. Our data confirm a need for
caution in extrapolating data from older cohorts to inform
management in young patients with breast cancer. It also
confirms the need to investigate treatment approaches in trials
involving sufficiently large numbers of younger women, which
would allow independent analysis to determine whether there are
major outcome differences and to understand why. Trials of more
treatment approaches specifically directed to younger patients
with breast cancer should be investigated (Aebi et al, 2000;
Colleoni et al, 2006; Narod, 2012). An additional limitation is that
adjuvant Herceptin has been used in the United Kingdom
routinely since 2005 so patients diagnosed with HER2þ disease
before this date will only have received Herceptin in the
metastatic setting. It is therefore possible that the outcome of
HER2 patients in the POSH cohort as a whole is inferior to HER2
patients diagnosed and treated in the United Kingdom since
2005. However, the impact of this is likely to be minimal as the
number of patients with HER2þ tumours diagnosed before 2005
(n¼ 298) and since 2005 (n¼ 381) included in this analysis is
relatively small.
In conclusion, this study has demonstrated that PREDICT, a
web-based tool that is easy to navigate for both patients and users,
is a valuable resource in providing accurate and reliable long-term
outcomes for younger patients. Although caution should
currently be used when interpreting the short-term survival
estimates in younger patients and the long-term estimates of
younger patients with ER tumours, it is intended that future
modifications of PREDICT will include the incorporation of the
POSH data set to allow for more robust estimates for younger
women with breast cancer. Accurate prediction of outcome at
both short- and long-term time points may be particularly
important to women trying to determine the optimal timing of
risk-reducing mastectomies.
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